The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | How the amyloidosis treatment landscape has transformed in recent years
Joan Bladé, MD, PhD, University of Barcelona, Barcelona, Spain, briefly discusses how the amyloidosis treatment landscape has transformed with the addition of daratumumab to cyclophosphamide, bortezomib, and dexamethasone, and the exciting implications that this combination therapy has for the future of amyloidosis treatment. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Disclosures
Honoraria for lectures: Janssen, BMS, Amgen, Takeda, Oncopeptides
